These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

879 related items for PubMed ID: 17510772

  • 21. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei--a report of 103 procedures.
    Smeenk RM, Verwaal VJ, Zoetmulder FA.
    Eur J Surg Oncol; 2006 Mar; 32(2):186-90. PubMed ID: 16303281
    [Abstract] [Full Text] [Related]

  • 22. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
    Sugarbaker PH.
    Eur J Surg Oncol; 2001 Apr; 27(3):239-43. PubMed ID: 11373099
    [Abstract] [Full Text] [Related]

  • 23. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL.
    J Clin Oncol; 2012 Jul 10; 30(20):2449-56. PubMed ID: 22614976
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
    Minicozzi A, Borzellino G, Momo EN, Segattini C, Pitoni F, Steccanella F, De Manzoni G.
    Ann Ital Chir; 2008 Jul 10; 79(4):231-9. PubMed ID: 19093624
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Inflammatory markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy.
    Chua TC, Chong CH, Liauw W, Zhao J, Morris DL.
    Ann Surg; 2012 Aug 10; 256(2):342-9. PubMed ID: 22750758
    [Abstract] [Full Text] [Related]

  • 29. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.
    Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FA.
    Br J Surg; 2001 Mar 10; 88(3):458-63. PubMed ID: 11260116
    [Abstract] [Full Text] [Related]

  • 30. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
    Choudry HA, Pai RK, Shuai Y, Ramalingam L, Jones HL, Pingpank JF, Ahrendt SS, Holtzman MP, Zureikat AH, Zeh HJ, Bartlett DL.
    Ann Surg Oncol; 2018 Jan 10; 25(1):76-82. PubMed ID: 29110275
    [Abstract] [Full Text] [Related]

  • 31. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.
    Yang XJ, Li Y, al-shammaa Hassan AH, Yang GL, Liu SY, Lu YL, Zhang JW, Yonemura Y.
    Ann Surg Oncol; 2009 Feb 10; 16(2):345-51. PubMed ID: 19018599
    [Abstract] [Full Text] [Related]

  • 32. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms.
    Yan TD, Links M, Xu ZY, Kam PC, Glenn D, Morris DL.
    Br J Surg; 2006 Oct 10; 93(10):1270-6. PubMed ID: 16838392
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
    Chua TC, Morris DL, Esquivel J.
    Ann Surg Oncol; 2010 May 10; 17(5):1330-6. PubMed ID: 20033321
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
    Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M.
    Ann Surg Oncol; 2007 Oct 10; 14(10):2790-7. PubMed ID: 17661150
    [Abstract] [Full Text] [Related]

  • 39. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M.
    Eur J Cancer; 2013 Oct 10; 49(15):3140-8. PubMed ID: 23831335
    [Abstract] [Full Text] [Related]

  • 40. Preoperative carcinoembryonic antigen level predicts prognosis in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Canbay E, Ishibashi H, Sako S, Mizumoto A, Hirano M, Ichinose M, Takao N, Yonemura Y.
    World J Surg; 2013 Jun 10; 37(6):1271-6. PubMed ID: 23467926
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.